• Type:
  • Category:

BRAIN Biotech AG Deep Dive 2023 | Revolutionizing the Food & Healthcare Industries with CFO


BRAIN Biotech AG Deep Dive: Key Takeaways

Michael Schneiders Discusses BRAIN Biotech AG’s Future

Introduction to BRAIN Biotech AG

Michael Schneiders, the CFO of BRAIN Biotech AG, presents a summary of the company’s Capital Markets Day highlights on the seat11a platform. Michael introduces BRAIN Biotech AG as an industrial biotech company with offspring in the pharma and diagnostic.


New Corporate Structure Unveiled

Michael presents BRAIN Biotech AG’s new corporate structure in three clearly defined business pillars: the enzyme and food ingredient products business BioProducts, custom research services BioScience, and the pipeline of breakthrough projects BioIncubator.


Strategic Aims and Growth Financing

Michael shares that the company aims to create a top 10 Global multi-niche food enzyme and ingredient champion. In addition, BRAIN will aim to carve out Akribion Genomics, a genome editing platform, as a subsidiary to attract growth financing.


Enabling Technology and Innovative Methods in Oncology

BRAIN Biotech AG offers critical enabling technology for the Biotransformation of the economy and has potentially discovered an innovative method to deplete cancer cells in oncology treatments.


Addressing Megatrends and Sustainable Food Production

Michael discusses how Brain Biotech addresses the megatrends of healthier and more sustainable food production. He believes industrialised countries will move increasingly away from livestock farming and find alternative protein sources, which Brain Biotech is happy to help produce through fermentation and precise fermentation.


Integration into Value Chain

Brain Biotech is wholly integrated into its value chain, allowing it to produce alternative proteins that are immaculate, healthy, and reasonable.


Global Ambitions and Financial Targets

Aiming for Top 10 in Enzyme Production

Michael shares BRAIN Biotech AG’s ambition to become a top 10 enzyme player globally within five years, doubling their current product revenue from around 40 million to about 80 million.


Organic Growth and EBITDA Margin Goals

They are looking for high organic growth in the group and to achieve a 15% (+/- 5PP) group EBITDA margin, 20% for products within five years. They plan to become a multi-niche player and the partner of choice for their global customer base.


International Production and Expansion

BRAIN Biotech AG already has an international production footprint and plans to expand its production capacity significantly. Finally, Michael talks about Brain Biotech’s yet-to-be-founded subsidiary, Akribion Genomics, and their vision of attracting external growth capital.

  • Why invest in BRAIN Biotech AG?
  • Future Nutrition will be Produced Differently
  • From Candidates to Industrial Production Processes
  • Merging BRAIN’s Products businesses under the Biocatalysts roof
  • One BioProducts: the big goals
  • Manufacturing footprint
  • Scales of fermentation
  • Growth Initiatives underway
  • Akribion Genomics – Vision and mission
  • Akribion Genomics – Unique Technology Platform
  • Akribion Genomics – A Very Exciting Business Opportunity
  • Efficient & Transparent Organization
michaelschneiders - BRAIN Biotech AG Deep Dive 2023 | Revolutionizing the Food & Healthcare Industries with CFO -%sitename%

Michael Schneiders
CFO | BRAIN Biotech AG​


This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Reviews for BRAIN Biotech AG Deep Dive 2023 | Revolutionizing the Food & Healthcare Industries with CFO
There are currently no reviews for BRAIN Biotech AG Deep Dive 2023 | Revolutionizing the Food & Healthcare Industries with CFO
Scroll to top